title: Qutenza®: a capsaicin 8% patch for the management of postherpetic neuralgia.
abstract: Despite currently available treatments, postherpetic neuralgia continues to be a challenging pain condition to treat. Many patients remain in pain or suffer side effects from the (combination) therapies. A patch containing 8% capsaicin (research code NGX-4010 and marketed under the trade name Qutenza(®)), approved both in the EU and USA, provides a localized therapy with effects lasting up to 12 weeks after a single 60-min application. This review will summarize clinical trial evidence on the safety, efficacy and unique attributes of this capsaicin 8% patch in the treatment of postherpetic neuralgia. The action of capsaicin on the transient receptor potential cation channel, subfamily V, member 1 receptors will be discussed.
authors.affiliation: University of California at San Diego, 9310 Campus Point Drive, Ste. A-114, La Jolla, CA 92037-1300, USA. mswallace@ucsd.edu
authors.forename: Mark
authors.initials: M
authors.lastname: Wallace
authors.forename: Marco
authors.initials: M
authors.lastname: Pappagallo
mesh_terms: D000279:Administration, Cutaneous; D002211:Capsaicin / Q000008:administration & dosage* / Q000009:adverse effects / Q000737:chemistry / Q000493:pharmacokinetics; D002986:Clinical Trials as Topic; D005060:Europe; D006801:Humans; D051474:Neuralgia, Postherpetic / Q000188:drug therapy*; D018689:Sensory System Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000737:chemistry / Q000493:pharmacokinetics; D050916:TRPV Cation Channels / Q000378:metabolism; D057968:Transdermal Patch; D014481:United States
chemical_list: D018689:Sensory System Agents; D050916:TRPV Cation Channels; C494482:TRPV1 protein, human; D002211:Capsaicin